- Home
- ESGL vs NKTX Comparison
ESGL vs NKTX Comparison
Compare ESGL & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- NKTX
- Stock Information
- Founded
- ESGL 1999
- NKTX 2015
- Country
- ESGL Singapore
- NKTX United States
- Employees
- ESGL N/A
- NKTX N/A
- Industry
- ESGL
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ESGL
- NKTX Health Care
- Exchange
- ESGL Nasdaq
- NKTX Nasdaq
- Market Cap
- ESGL 123.1M
- NKTX 123.5M
- IPO Year
- ESGL N/A
- NKTX 2020
- Fundamental
- Price
- ESGL $3.23
- NKTX $1.80
- Analyst Decision
- ESGL
- NKTX Strong Buy
- Analyst Count
- ESGL 0
- NKTX 6
- Target Price
- ESGL N/A
- NKTX $14.40
- AVG Volume (30 Days)
- ESGL 84.3K
- NKTX 463.1K
- Earning Date
- ESGL 09-03-2025
- NKTX 08-12-2025
- Dividend Yield
- ESGL N/A
- NKTX N/A
- EPS Growth
- ESGL N/A
- NKTX N/A
- EPS
- ESGL N/A
- NKTX N/A
- Revenue
- ESGL $6,099,784.00
- NKTX N/A
- Revenue This Year
- ESGL N/A
- NKTX N/A
- Revenue Next Year
- ESGL N/A
- NKTX N/A
- P/E Ratio
- ESGL N/A
- NKTX N/A
- Revenue Growth
- ESGL N/A
- NKTX N/A
- 52 Week Low
- ESGL $0.90
- NKTX $1.31
- 52 Week High
- ESGL $3.87
- NKTX $8.23
- Technical
- Relative Strength Index (RSI)
- ESGL 58.34
- NKTX 51.45
- Support Level
- ESGL $2.69
- NKTX $1.68
- Resistance Level
- ESGL $3.87
- NKTX $1.84
- Average True Range (ATR)
- ESGL 0.30
- NKTX 0.08
- MACD
- ESGL -0.05
- NKTX 0.01
- Stochastic Oscillator
- ESGL 45.87
- NKTX 80.95
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.